Which patients with oligodendrogliomas are good candidates for vorasidenib to delay radiation therapy?

Patients with WHO 2 tumors without enhancement who have had gross total resections and have no worrisome molecular pathology findings usually do better with upfront vorasidenib, delaying more aggressive interventions with chemotherapy and radiation, often for years, sometimes decades, and occasional...